Predictive factors of six-week mortality in critically ill patients with SARS-CoV-2 : A multicenter prospective study
Copyright © 2021 Elsevier España, S.L.U. and SEMICYUC. All rights reserved..
OBJECTIVE: The objective of the study is to identify the risk factors associated with mortality at six weeks, especially by analyzing the role of antivirals and munomodulators.
DESIGN: Prospective descriptive multicenter cohort study.
SETTING: 26 Intensive care units (ICU) from Andalusian region in Spain.
PATIENTS OR PARTICIPANTS: Consecutive critically ill patients with confirmed SARS-CoV-2 infection were included from March 8 to May 30.
INTERVENTIONS: None.
VARIABLES: Variables analyzed were demographic, severity scores and clinical condition. Support therapy, drug and mortality were analyzed. An univariate followed by multivariate Cox regression with propensity score analysis was applied.
RESULTS: 495 patients were enrolled, but 73 of them were excluded for incomplete data. Thus, 422 patients were included in the final analysis. Median age was 63 years and 305 (72.3%) were men. ICU mortality: 144/422 34%; 14 days mortality: 81/422 (19.2%); 28 days mortality: 121/422 (28.7%); 6-week mortality 152/422 36.5%. By multivariable Cox proportional analysis, factors independently associated with 42-day mortality were age, APACHE II score, SOFA score at ICU admission >6, Lactate dehydrogenase at ICU admission >470U/L, Use of vasopressors, extrarenal depuration, %lymphocytes 72h post-ICU admission <6.5%, and thrombocytopenia whereas the use of lopinavir/ritonavir was a protective factor.
CONCLUSION: Age, APACHE II, SOFA>value of 6 points, along with vasopressor requirements or renal replacement therapy have been identified as predictor factors of mortality at six weeks. Administration of corticosteroids showed no benefits in mortality, as did treatment with tocilizumab. Lopinavir/ritonavir administration is identified as a protective factor.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
Medicina intensiva - 46(2022), 4 vom: 21. Apr., Seite 179-191 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
2494G1JF75 |
|---|
| Anmerkungen: |
Date Completed 26.04.2022 Date Revised 21.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.medine.2021.02.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339907827 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339907827 | ||
| 003 | DE-627 | ||
| 005 | 20231226003936.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.medine.2021.02.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1132.xml |
| 035 | |a (DE-627)NLM339907827 | ||
| 035 | |a (NLM)35461665 | ||
| 035 | |a (PII)S2173-5727(22)00054-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Estella, Á |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Predictive factors of six-week mortality in critically ill patients with SARS-CoV-2 |b A multicenter prospective study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.04.2022 | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier España, S.L.U. and SEMICYUC. All rights reserved. | ||
| 520 | |a OBJECTIVE: The objective of the study is to identify the risk factors associated with mortality at six weeks, especially by analyzing the role of antivirals and munomodulators | ||
| 520 | |a DESIGN: Prospective descriptive multicenter cohort study | ||
| 520 | |a SETTING: 26 Intensive care units (ICU) from Andalusian region in Spain | ||
| 520 | |a PATIENTS OR PARTICIPANTS: Consecutive critically ill patients with confirmed SARS-CoV-2 infection were included from March 8 to May 30 | ||
| 520 | |a INTERVENTIONS: None | ||
| 520 | |a VARIABLES: Variables analyzed were demographic, severity scores and clinical condition. Support therapy, drug and mortality were analyzed. An univariate followed by multivariate Cox regression with propensity score analysis was applied | ||
| 520 | |a RESULTS: 495 patients were enrolled, but 73 of them were excluded for incomplete data. Thus, 422 patients were included in the final analysis. Median age was 63 years and 305 (72.3%) were men. ICU mortality: 144/422 34%; 14 days mortality: 81/422 (19.2%); 28 days mortality: 121/422 (28.7%); 6-week mortality 152/422 36.5%. By multivariable Cox proportional analysis, factors independently associated with 42-day mortality were age, APACHE II score, SOFA score at ICU admission >6, Lactate dehydrogenase at ICU admission >470U/L, Use of vasopressors, extrarenal depuration, %lymphocytes 72h post-ICU admission <6.5%, and thrombocytopenia whereas the use of lopinavir/ritonavir was a protective factor | ||
| 520 | |a CONCLUSION: Age, APACHE II, SOFA>value of 6 points, along with vasopressor requirements or renal replacement therapy have been identified as predictor factors of mortality at six weeks. Administration of corticosteroids showed no benefits in mortality, as did treatment with tocilizumab. Lopinavir/ritonavir administration is identified as a protective factor | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Corticoides | |
| 650 | 4 | |a Corticosteroids | |
| 650 | 4 | |a ICU | |
| 650 | 4 | |a Lopinavir/ritonavir | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Tocilizumab | |
| 650 | 4 | |a UCI | |
| 650 | 7 | |a Lopinavir |2 NLM | |
| 650 | 7 | |a 2494G1JF75 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 700 | 1 | |a Garcia Garmendia, J L |e verfasserin |4 aut | |
| 700 | 1 | |a de la Fuente, C |e verfasserin |4 aut | |
| 700 | 1 | |a Machado Casas, J F |e verfasserin |4 aut | |
| 700 | 1 | |a Yuste, M E |e verfasserin |4 aut | |
| 700 | 1 | |a Amaya Villar, R |e verfasserin |4 aut | |
| 700 | 1 | |a Estecha, M A |e verfasserin |4 aut | |
| 700 | 1 | |a Yaguez Mateos, L |e verfasserin |4 aut | |
| 700 | 1 | |a Cantón Bulnes, M L |e verfasserin |4 aut | |
| 700 | 1 | |a Loza, A |e verfasserin |4 aut | |
| 700 | 1 | |a Mora, J |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández Ruiz, L |e verfasserin |4 aut | |
| 700 | 1 | |a Díez Del Corral Fernández, B |e verfasserin |4 aut | |
| 700 | 1 | |a Rojas Amezcua, M |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez Higueras, M I |e verfasserin |4 aut | |
| 700 | 1 | |a Díaz Torres, I |e verfasserin |4 aut | |
| 700 | 1 | |a Recuerda Núñez, M |e verfasserin |4 aut | |
| 700 | 1 | |a Zaheri Beryanaki, M |e verfasserin |4 aut | |
| 700 | 1 | |a Rivera Espinar, F |e verfasserin |4 aut | |
| 700 | 1 | |a Matallana Zapata, D F |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno Cano, S G |e verfasserin |4 aut | |
| 700 | 1 | |a Gimenez Beltrán, B |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz, N |e verfasserin |4 aut | |
| 700 | 1 | |a Sainz de Baranda Piñero, A |e verfasserin |4 aut | |
| 700 | 1 | |a Bustelo Bueno, P |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno Barriga, E |e verfasserin |4 aut | |
| 700 | 1 | |a Rios Toro, J J |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez Ruiz, M |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez González, C |e verfasserin |4 aut | |
| 700 | 1 | |a Breval Flores, A |e verfasserin |4 aut | |
| 700 | 1 | |a de San José Bermejo Gómez, A |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz Cabello Jimenez, M A |e verfasserin |4 aut | |
| 700 | 1 | |a Guerrero Marín, M |e verfasserin |4 aut | |
| 700 | 1 | |a Ortega Ordiales, A |e verfasserin |4 aut | |
| 700 | 1 | |a Tejero-Aranguren, J |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez Mejías, C |e verfasserin |4 aut | |
| 700 | 1 | |a Gomez de Oña, J |e verfasserin |4 aut | |
| 700 | 1 | |a de la Hoz, C |e verfasserin |4 aut | |
| 700 | 1 | |a Ocaña Fernández, D |e verfasserin |4 aut | |
| 700 | 1 | |a Ibañez Cuadros, S |e verfasserin |4 aut | |
| 700 | 1 | |a Garnacho Montero, J |e verfasserin |4 aut | |
| 700 | 0 | |a Work Group of Infectious Disease (GTEI) de la Sociedad Andaluza de Medicina Intensiva y Unidades coronarias SAMIUC |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicina intensiva |d 2017 |g 46(2022), 4 vom: 21. Apr., Seite 179-191 |w (DE-627)NLM25948640X |x 2173-5727 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2022 |g number:4 |g day:21 |g month:04 |g pages:179-191 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.medine.2021.02.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2022 |e 4 |b 21 |c 04 |h 179-191 | ||